

Gibson Dunn Advises US WorldMeds on Acquisition of Adaptimmune Therapeutics's TECELRA, lete-cel, afami-cel, and uza-cel Cell Therapies and Concurrent Financing

Firm News | July 28, 2025

Gibson Dunn is advising US WorldMeds, a specialty pharmaceutical company, on its acquisition of Adaptimmune Therapeutics's TECELRA, lete-cel, afami-cel, and uza-cel cell therapies. Gibson Dunn also advised US WorldMeds on a financing, of which the first tranche will be used to provide funds for the acquisition, led by funds managed by Oaktree Capital Management, L.P., with participation from funds managed by Athyrium Capital Management, LP.

Gibson Dunn regularly advises life sciences companies on complex acquisition and financing transactions in the cell therapy and biopharmaceutical sectors.

The Gibson Dunn team includes Branden Berns, Jin Hee Kim, Todd Trattner, Alison Beal, Yair Galil, Sam Shapiro, Iris Crabtree Hill, and Matthew Staugaard.

Related Capabilities

[Mergers and Acquisitions](#)

[Life Sciences](#)

[Finance](#)

[FDA and Health Care](#)

[Tax](#)

[Intellectual Property](#)

[Technology Transactions](#)

[Executive Compensation and Employee Benefits](#)

[Real Estate](#)

[Privacy, Cybersecurity, and Data Innovation](#)

[Antitrust and Competition](#)

[Private Equity](#)